What is Onglyza?

Onglyza (saxagliptin) is a type 2 diabetes medication that was approved by the FDA on July 31, 2009. The drug is used to help control blood sugar in type 2 diabetes patients who do not suffer from diabetic ketoacidosis – a condition where the body breaks down fat cells, creating a toxic amount of ketones in the blood stream.

Since its introduction to the diabetes drug market, it has been a popular choice among doctors and patients because weight gain is not a common side effect, as it can be with other similar diabetes medications. The medication saw sales of nearly 800 million dollars in 2015, and that number is expected to increase each year.

How To File An Onglyza Heart Attack Lawsuit

What Are Complications Of Onglyza?

Unfortunately, there has been some concern over serious side effects that may be associated with the drug. Several studies conducted since 2011 have suggested it may increase the risk of heart failure (heart attacks) or pancreatic cancer in some patients.

Heart Failure

A study conducted in 2015 known as the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) involved over 16,000 patients. The study concluded that it increased the risk of heart failure hospitalizations by roughly 27 percent.

On April 5, 2016, the FDA released an updated safety communication requiring the label to include warnings about heart failure.

Pancreatic Cancer

The FDA has also released safety communications about the risk of pancreatic cancer and severe joint pain in patients who use the drug.

Several diabetes drugs, including Onglyza, have been linked to an increased risk of pancreatic cancer. Pancreatic cancer is a particularly troubling cancer as it rarely shows any signs or symptoms of its presence until the tumor has grown large enough to be a life-threatening concern. Pancreatic cancer can also be brought on by pancreatitis.

UCLA researchers determined that diabetes drugs like Onglyza increase the mass of the pancreas. Additionally, according to a study published in Gastroenterology, people who take these drugs to help manage diabetes are 2.7 times more likely to develop pancreatic cancer.

What Legal Action Has Been Taken Against Onglyza?

Lawsuits are currently being investigated against the manufacturers of saxagliptin, AstraZeneca. If you have experienced negative side effects after taking this medication, you may be eligible to receive compensation for your pain and suffering.

Lawsuits will seek compensation for lost wages, physical damages, and more. Settlements in lawsuits will also cover the cost of medical expenses related to these complications.

Settlements in lawsuits are expected to be substantial due to the serious of the alleged complications. If you have suffered complications after taking this drug, you should speak with an attorney as soon as possible. There are very specific time deadlines that must be met when filing dangerous drug lawsuits. If you miss the deadline, your claim could be lost forever.

What Claims Are Filed Against Onglyza?

Onglyza is classified in a group of drugs known as Dipeptidyl peptidase-4, or DPP-4 inhibitors. The FDA has been monitoring complaints related to these drugs since they were first introduced to the market in 2006. It has been named in several FDA safety communications. They can be found in the table below.

The information on this site is ATTORNEY ADVERTISING by Attorney Lawrence J. Buckfire of the Buckfire Law Firm. Office address is 29000 Inkster Road, Suite 150, Southfield, MI 48034 and telephone number is (866) 280-4722.